Martín-Varillas, J.L., Sanchez-Bilbao, L., Calvo-Río, V., et al. (2022) Long-Term Follow-Up of Certolizumab Pegol in Uveitis Due to Immune-Mediated Inflammatory Diseases: Multicentre Study of 80 Patients. RMD Open, 8, e002693.
https://doi.org/10.1136/rmdopen-2022-002693

has been cited by the following article:

• TITLE: Progress in the Use of Glucocorticoids and Biological Agents in Non-Infectious Uveitis

  AUTHORS: Yuxuan Liu, Xunyu Zou, Shizhou Cheng, Zuhai Zhang

  KEYWORDS: Non-Infectious Uveitis, Glucocorticoids, Biological Agents

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.2, February 7, 2024

  ABSTRACT: One of the main immune-mediated diseases that lead to avoidable blindness is non-infectious uveitis. Glucocorticoids are the first-line therapy choice for noninfectious uveitis; however, biologics are also showing promise in the management of this condition. The description of glucocorticoid and biologic usage in non-infectious uveitis is the main topic of this paper.